Business Context and Reporting Period
Oculis Holding AG filed a shell company report on Form 20-F following the consummation of its business combination with European Biotech Acquisition Corp. (EBAC) on March 2, 2023. Oculis Holding AG was incorporated in Switzerland on October 31, 2022 to facilitate the transaction and became the parent of Oculis’ operating business. The report was signed on March 7, 2023.
This is not an annual operating report. The filing incorporates Oculis’ historical financial statements and management discussion from the prospectus, including audited years ended December 31, 2021 and 2020 and unaudited interim periods through September 30, 2022. The filing text provided does not include clear current-period revenue, operating loss, cash-flow, or margin figures.
Key Financial Metrics, Capitalization and Liquidity
| Metric | Reported amount or status |
|---|---|
| Pro forma cash and cash equivalents | CHF 106.991 million as of September 30, 2022, after giving effect to the business combination, PIPE financing, and convertible loan agreements |
| Pro forma total equity and capitalization | CHF 113.736 million |
| Pro forma accumulated losses | CHF 141.787 million |
| Convertible financing | $19.670 million, converted into New Parent shares at $10.00 per share |
| PIPE financing | 7,118,891 shares issued at $10.00 per share for gross proceeds of $71.189 million |
| EBAC share redemptions | 11,505,684 shares redeemed for approximately $117.487 million |
| Ordinary shares outstanding at closing | 32,733,373 |
| Warrants outstanding at closing | 4,403,294 warrants, each exercisable for one ordinary share at $11.50 per share |
The filing does not provide a clear value for revenue, net income or loss, operating cash flow, free cash flow, debt balances after conversion, liquidity runway, or operating margins in the text supplied. Oculis’ historical financial information is incorporated by reference from the prospectus.
The company has never declared or paid cash dividends and does not expect to pay dividends in the foreseeable future. It intends to retain earnings for operations and expansion.
Material Changes Versus the Prior Comparable Period
- The principal change was the transformation from a newly formed acquisition vehicle into the listed parent of Oculis following the March 2, 2023 business combination.
- EBAC’s public shares and warrants were converted into Oculis Holding AG ordinary shares and warrants, which began trading on Nasdaq under OCS and OCSAW.
- The company raised $71.189 million in PIPE gross proceeds and converted $19.670 million of convertible loans into shares.
- Approximately $117.487 million was paid to redeem 11.506 million EBAC Class A shares before closing.
- Oculis SA was expected to merge into a wholly owned subsidiary of Oculis Holding AG in the first half of 2023; the filing states this step had not yet occurred as of the report date.
Guidance, Outlook, Risks and Unusual Items
No quantitative financial guidance is provided in the filing. Forward-looking matters include the timing and outcomes of clinical trials, regulatory submissions and approvals, commercialization, partnerships, milestone and royalty payments, future revenue and expenses, capital requirements, additional financing needs, market opportunity, competition, intellectual property protection, and the ability to maintain Nasdaq listing.
- Oculis is a development-stage biotechnology business, and its product candidates remain subject to clinical, regulatory, safety, efficacy and commercialization risks.
- The company may require additional financing; the filing does not provide a definitive liquidity runway or funding date.
- Clinical and regulatory delays, unfavorable trial results, manufacturing or supply issues, and inability to obtain approvals could materially affect operations.
- Competition, dependence on collaborations and licenses, intellectual property disputes, and possible milestone or royalty obligations may affect future economics.
- Macroeconomic conditions, the COVID-19 pandemic, the Russia-Ukraine conflict, legal proceedings and regulatory changes are identified as potential sources of uncertainty.
- The company is a foreign private issuer and emerging growth company and may rely on reduced SEC reporting and governance requirements. It intends to follow certain Swiss home-country governance practices rather than all Nasdaq requirements.
- EBAC’s historical financial statements included an explanatory going-concern paragraph from its auditor, although those statements relate to the pre-combination acquisition vehicle.
Investor Verification Checklist
- Verify Oculis’ latest audited financial statements, revenue, operating losses, cash burn, debt and liquidity runway in the prospectus and subsequent filings.
- Reconcile the stated pro forma CHF 106.991 million cash balance with redemption payments, transaction expenses, PIPE proceeds and converted financing.
- Confirm the completion and accounting treatment of the planned third merger involving Oculis SA.
- Assess dilution from 4,403,294 outstanding warrants, 3,793,995 contingently forfeitable earnout shares, the 2023 equity plan and other conditional or convertible securities.
- Review clinical-trial timelines, regulatory milestones, product-candidate safety and efficacy data, and the company’s dependence on licensing and collaboration agreements.
- Review lock-up, registration-rights and related-party arrangements, as well as the concentration of ownership among major investors.